NASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis $595.22 +26.31 (+4.62%) As of 03:40 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Regeneron Pharmaceuticals Stock (NASDAQ:REGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get REGN alerts:Sign Up Key Stats Today's Range$566.99▼$596.5050-Day Range$546.39▼$744.8352-Week Range$525.99▼$1,211.20Volume1.13 million shsAverage Volume739,086 shsMarket Capitalization$65.07 billionP/E Ratio15.55Dividend Yield0.15%Price Target$912.20Consensus RatingModerate Buy Company OverviewRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More… Regeneron Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreREGN MarketRank™: Regeneron Pharmaceuticals scored higher than 96% of companies evaluated by MarketBeat, and ranked 44th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 18 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth5.85% Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 5.85% in the coming year, from $35.92 to $38.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 15.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.70.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 15.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.43.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.34. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.57% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently decreased by 6.81%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRegeneron Pharmaceuticals has a dividend yield of 0.15%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Regeneron Pharmaceuticals is 2.30%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Regeneron Pharmaceuticals will have a dividend payout ratio of 2.31% next year. This indicates that Regeneron Pharmaceuticals will be able to sustain or increase its dividend.Read more about Regeneron Pharmaceuticals' dividend. Sustainability and ESG2.3 / 5Environmental Score-2.69 Percentage of Shares Shorted2.57% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently decreased by 6.81%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News Sentiment0.67 News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 56 news articles for Regeneron Pharmaceuticals this week, compared to 29 articles on an average week.Search InterestOnly 24 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.48% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Stock News HeadlinesRegeneron Pharmaceuticals Inc (REGN) Q1 2025 Earnings Call Highlights: Strong Dupixent Sales ...April 30 at 2:10 AM | gurufocus.comRegeneron's first-quarter results miss on lower Eylea demandApril 29 at 10:14 PM | msn.comTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has hit extremes, it’s spelled doom for stocks — and soaring gains for gold. Today, the Indicator is flashing a historic all-time high. Meanwhile, Buffett is quietly hoarding $325 billion in cash — and insiders believe he’s about to make a gold move big enough to shock Wall Street. Garrett Goggin has the names of 4 companies likely to benefit — if you move fast. April 30, 2025 | Golden Portfolio (Ad)Regeneron Pharmaceuticals Stock Sinks as Eylea Q1 Sales Trail EstimatesApril 29 at 10:14 PM | msn.comRegeneron Pharma Margins Tighten As Competition Grows, Stock SlidesApril 29 at 2:52 PM | benzinga.comTop Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and MoreApril 29 at 12:06 PM | investopedia.comRegeneron Stock Plummets After Earnings MissApril 29 at 9:11 AM | barrons.comRegeneron Pharma's first-quarter results miss on lower Eylea demandApril 29 at 8:28 AM | reuters.comSee More Headlines REGN Stock Analysis - Frequently Asked Questions How have REGN shares performed this year? Regeneron Pharmaceuticals' stock was trading at $712.33 at the start of the year. Since then, REGN stock has decreased by 17.2% and is now trading at $590.09. View the best growth stocks for 2025 here. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings data on Tuesday, April, 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by $0.61. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% on a year-over-year basis. Read the conference call transcript. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and more. Who are Regeneron Pharmaceuticals' major shareholders? Top institutional shareholders of Regeneron Pharmaceuticals include GAMMA Investing LLC (0.75%), Bank of New York Mellon Corp (0.64%), Assenagon Asset Management S.A. (0.44%) and Sumitomo Mitsui Trust Group Inc. (0.28%). Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Jason Pitofsky, Marc Tessier-Lavigne, Christine A Poon, Michael S Brown, Bonnie L Bassler, Huda Y Zoghbi and N Anthony Coles. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Record date for 3/20 Dividend2/20/2025Ex-Dividend for 3/20 Dividend2/20/2025Dividend Payable3/20/2025Last Earnings4/29/2025Today4/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees11,900Year Founded1988Price Target and Rating Average Stock Price Target$941.12 High Stock Price Target$1,300.00 Low Stock Price Target$150.00 Potential Upside/Downside+61.4%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage26 Analysts Profitability EPS (Most Recent Fiscal Year)$38.28 Trailing P/E Ratio15.24 Forward P/E Ratio16.24 P/E Growth2.34Net Income$4.41 billion Net Margins31.07% Pretax Margin33.66% Return on Equity16.32% Return on Assets12.76% Debt Debt-to-Equity Ratio0.09 Current Ratio4.73 Quick Ratio3.95 Sales & Book Value Annual Sales$14.20 billion Price / Sales4.49 Cash Flow$38.29 per share Price / Cash Flow15.23 Book Value$268.50 per share Price / Book2.17Miscellaneous Outstanding Shares109,325,000Free Float101,147,000Market Cap$63.76 billion OptionableOptionable Beta0.44 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:REGN) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.